Eurofins Biomnis Clinical Trials has been involved in the field of specialised biology associated with clinical trials since 1998.
Based within a specialised clinical diagnostics laboratory, the unit has direct access to daily biological expertise in diagnostics and therapeutic monitoring for drug candidates.
Accredited for Research Tax Credits, the unit supports numerous healthcare sector players (pharmaceutical companies, CROs, biotechs, medical device manufacturers and hospitals) in their clinical research and development projects.
To meet your diverse needs, including clinical diagnosis, therapeutic monitoring, evaluating the tolerance and efficacy of drug candidates, innovative testing, and new biomarkers, Eurofins Biomnis Clinical Trials offers quality management services for eclectic projects and develops high-value tests.
Thanks to our extensive experience in conducting a wide range of high-value niche analyses, we can offer you the expertise of various biologists, as well as the knowledge and skills of highly qualified engineers, scientists and technicians. This enables us to provide you with comprehensive solutions based on feasibility studies.
Eurofins Biomnis Clinical Trials has a multidisciplinary, proactive project team that complies with GCP and GCPL standards. The team has acquired knowledge through numerous method validations in accordance with the main reference standards (COFRAC, FDA and EMEA), enabling us to respond to clinical research and development projects in France and internationally.
Vision
Eurofins Biomnis Clinical Trials is at the forefront of scientific and technological advances. With a panel of multidisciplinary experts and a fleet of state-of-the-art automated equipment, we ensure that the innovative and exploratory tests used in today's clinical trials are integrated into tomorrow's Specialised Biology catalogue.
Value
Respect for patients can only be achieved by providing unfaltering quality and reliability in the services we deliver.
Promise
Promises only have meaning if contractual commitments are honoured.
Eurofins Biomnis Clinical Trials in key figures
- More than 300 studies to its credit
- More than 6,000 Specialised Biology files associated with clinical trials per year
- Breakdown of studies:
4.23% preclinical
38.85% Phase I
13.46% Phase II
10.38% Phase III
2.69% Phase IV
30.38%: various projects (e.g. pilot studies, epidemiological studies, technology transfer and R&D projects).